CA2166121A1 - Hormonal method of acne therapy - Google Patents
Hormonal method of acne therapyInfo
- Publication number
- CA2166121A1 CA2166121A1 CA002166121A CA2166121A CA2166121A1 CA 2166121 A1 CA2166121 A1 CA 2166121A1 CA 002166121 A CA002166121 A CA 002166121A CA 2166121 A CA2166121 A CA 2166121A CA 2166121 A1 CA2166121 A1 CA 2166121A1
- Authority
- CA
- Canada
- Prior art keywords
- hormone
- constituent
- daily
- units
- hormonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Abstract
A method for controlling acne and a hormonal composition for providing acne therapy are provided. Two hormone constituents are packaged spatially separated in a packaging unit for chronologically sequential, oral admin-istration. Each hormone constituent is provided in the form of a plurality of daily hormone units accommodated spatially separately and individually removable in the packaging unit. A first of the hormone constituents contains essentially only an estrogen preparation as active hormonal substance that effects an increase in the sexual hormone-bonding globulins (SHBG). The second hormone constituent contains in estrogen preparation and an anti-androgen preparation in combination. The total plurality of daily units is equal days in the desired cycle.
Preferably, the first hormone constituent comprises 5 through 14 daily units and the second hormone constituent comprises 23 through 14 daily units so that the plurality of daily units of the first hormone constituent is lower than the plurality of daily units of the second hormone constituent.
Preferably, the first hormone constituent comprises 5 through 14 daily units and the second hormone constituent comprises 23 through 14 daily units so that the plurality of daily units of the first hormone constituent is lower than the plurality of daily units of the second hormone constituent.
Description
'~JCI~ OEH~lEP.T + BI~EH~IE~:T RN: 0~ 23~7~41 13~15. 1~-~l 13: :~7 #~gl~! P. O2~11 PAT~NT
ATTY. REF. P95,3119 n~r. N~T~OD OF ~N~ ~RAP~
~A~K~OUND OF T~ v~ ON
The invention is dlrected to a hormonal me~hod for acne therapy, wherein two hormone ~onstituents are packa~ed ~pa~ially separated in a packaging unit for chronologically sequential, oral adm$~1~tration. ~ach hormonal constituent comprises a plurality of daily hormone units accommoda~ed spatially separately and individuAlly re~ d~le in the packaging unit. The ~irst of ~he hormone constituents contains only ~n estrogen prepa~a~ion as active hormonal substance which effeats an increase in the ~exu~l hormone-bonding globulins (SHBG). Th~ second hormone constituent contains an es~rogen preparation and an anti-androgen preparatlon in combination. The method of the invention comprises controlling acne by administering the hormonal constituents to a hum~n patient ~u~fering from acne.
Hormonal me~n~ for treating acne has ~een known for a long time, this being available as co~bina~ion prepara-tion ~or ~ases of ~eborrhea, acne and alopecia ~ndro-geneti~a as well as for less se~ious cases of hirsutism.
The prior mixed hormone ~onstituent~ contain 2 mg cypro-~eroneacetate as ~nti-~ndrogen preparati~n and 35 ~g ethinyl e~tradiol as ~n es~rogen pr~para~ion. A combina-tion preparation with 2 mg ~hloromadinone~et~te and 50 ~g me~ranol has a similar ~ffe~t.
ATTY. REF. P95,3119 n~r. N~T~OD OF ~N~ ~RAP~
~A~K~OUND OF T~ v~ ON
The invention is dlrected to a hormonal me~hod for acne therapy, wherein two hormone ~onstituents are packa~ed ~pa~ially separated in a packaging unit for chronologically sequential, oral adm$~1~tration. ~ach hormonal constituent comprises a plurality of daily hormone units accommoda~ed spatially separately and individuAlly re~ d~le in the packaging unit. The ~irst of ~he hormone constituents contains only ~n estrogen prepa~a~ion as active hormonal substance which effeats an increase in the ~exu~l hormone-bonding globulins (SHBG). Th~ second hormone constituent contains an es~rogen preparation and an anti-androgen preparatlon in combination. The method of the invention comprises controlling acne by administering the hormonal constituents to a hum~n patient ~u~fering from acne.
Hormonal me~n~ for treating acne has ~een known for a long time, this being available as co~bina~ion prepara-tion ~or ~ases of ~eborrhea, acne and alopecia ~ndro-geneti~a as well as for less se~ious cases of hirsutism.
The prior mixed hormone ~onstituent~ contain 2 mg cypro-~eroneacetate as ~nti-~ndrogen preparati~n and 35 ~g ethinyl e~tradiol as ~n es~rogen pr~para~ion. A combina-tion preparation with 2 mg ~hloromadinone~et~te and 50 ~g me~ranol has a similar ~ffe~t.
2~ The ~now~n hormonal regimens for acne therapy, as se~
forth above, ~re a matter of combination prepAra~io~s that are also e~ective as ovulation inhibitors in ~ddition to their e~ficacy in combatting acne. In~of~r as the desire~
cycle duration amounts th 28 days, these hormones are admlnistered for 21 days, whereby ~he hormone ~o~blnations are given in 21 daily ~nits, followed by a seven-d~y pause in which no admin~stration of hormone is given. Thi~ pause VC~ EH~lERT + BOEHMERT P~ 01S1~37~41 1g~57 12-21 13: 37 #~;gl21 F .12~
.. . . .. ., . . . ., .. ., .. , . _ . . _ . . .. . . ..... .. ... . .
2l66l2l . .
is followed by a wlthd~awal ~leeding that simulates ~he natural menstru~l ble~dlng.
The prior hormonal ther~pies have definitely pro~en them~elves; however, a further improvement in the ability to ~e able ~o ~ombat acne is 3till desired.
German ~ett~rs Paten~ ~1 04 3B5 dis~lose~ an ovulation-inhibitlng means for hormonal contracep~ion having two hormone con~tituents packaged ~patially separa~ed in a packagin~ unit ~or chronologically sequen-tial, oral admini~tration, each hormone constituent beingre~pectively composed of a plurality o~ ~ily hormone units accom~odated ~patially sep~ratel~ ~nd individually ~e~v-able in thq packaging unit, whereby a first ~f the hormone constituents çontain~ essentially only ~n estrogen prepara-tion as act~ve horm~nal subætan~e that effe~ts a disturb-ance of the follicle stimulation and the second hormon~
constituent contains a combination of an es~rogen prepara-tion and a ~estagen preparation in a dose at least adequate to inhibit ovulati~n, whe~by the ~o~al nu~ber of daily hor~ne units is equal to the total number of days in the desired cy~le, ~he El~st hormone constituent compriseæ 5 through 14 d~lly unt,t~ and the second hormone con6tituent ~omp~ises 23 throug!- 14 dally uni~s, where~y the plurality ~f ~aily units of the first hormone constituent is lower ~5 than the pl~rality of daily units o~ the second hormone ~onstituent.
In this kn~wn ovul~ti~n-inhiblting method, the estrogen preparation can, for ex~ple, comprise ethinyl estradiol and the g6stagen or anti-androgen prep2r~tion can ~ompxi~e cyproteroneacetate or chloromadinoneacet~te.
It is ~:h2~ra~eristi~ o~ the a.bov~-de~cri}~ed ovula~ion-inhi~iting me~ns th~t the adminis~ra~ion ensues without pAuse wi~h a constant estrogen dose, as a result whereof a uniform e8trogen level is maintained.
IJC~ EH~ERT + E~ EH~EF~T R~ 01~161;~337~41 l~lg5. 1~ 37 #~ )4~
SUMMARY OF THE INVENTIO~
The object of the lnvention is to develop an imp~oved hormonal method for tre~tlng ~cne such that an improved a~ne ~her~py i~ enabled.
This o~ject i~ invPnti~ely achieved in th~t the total plurality of daily unit~ is equal ~o ~he t~tal plurality of d~y~ in the desired cycle, in that the first hormon~ constituent comprises 5 ~hrough 14 daily units and ~he ~econd hormone ~onstituent ~omprises ~3 through 14 daily units; and in th~t the plurality of daily uni~5 of the first hormone constituent i5 lower than the plurali~y of daily units of th~ ~econd hormone ~ons~ituent.
It can thereby ~e provided that at least one of the e~trogen preparatlon~ aomprises at least one component from the group encompassing ethinyl e~tradiol, mestranol, o~her syntheti~ es~rogens as well as hormon~l eompounds that ~uickly ~plit off ~t l~ast one of the aforementione~
ho~mone aomponents after ingestion.
The inven~ion also provides that the e~rogen preparations of the first and of the se~ond hormone con~tituen~ ~re identical in terms of their type and/or their effe~tive ~ose.
It c~n ~lso be inven~vely provided that the first and the second hormone con~tituents comprise ethinyl ~S estradiol wi~h ~ concentration of 15 - 35 ~g per dally unit as estrogen preparation.
The in~ention also proposes that the an~i-androgen preparation comprise~ cyproteroneacetate.
It Gan al~o be provided ac~ording to ~he inven~ion th~t the anti-androgen prepar~tlon cont~in~ abou~ mg cyproteroneacet~te per d~ily unit.
A further embodiment of the invention is ~h~ac-teri~ed in that the anti-androgen prep~ration comprises chlorodinoneacetate.
'JCI~I:BClEHMEF:T + E:OEH~`1EF~T I~lN:OE~ 337g41 1~ 1 13:37 #6~1~! p.lZ15~11 _, _ _ _ _ .... . . . . . . . . . .. . . .. . . . . . .. . . . .. . . ... . .
T~e invention also prop~6e~ that the anti-androgen preparation ao~prises approximately 1-3 mg chloro~inone-acetate per d~ily uni~.
The invent~on thereby also propose~ that the anti-andrcgen preparation oo~p~ises dieneogest.
It ~an also be pr~vi~ed that the anti-androgen preparation compri~es approxi~ately 1-3 mg dieneogest per daily unit.
I~ ¢an also be ~nventively provided that thç total numbe~ o~ daily uni~s amounts to Z8.
The ~n~ention also preferably p~ovide~ that the first hormone consti~Uent comprises at mos~ 10 d~ily ~nlts.
In a pre~erred embodimen~ of the method, the firs~
hormone constituent comprises 7 daily units and the sec~n~
hormone constituent comprise~ 21 daily units.
Finally, th~ in~ention also teach~s the employment of the hormonal means of the invention fo~ Acne ~herapy.
The invention is ~ased on ~he surp~i6ing perception that one succeeds in ena~ing an improved acne ~her~py when, in conformi~y with the ovulation-inhibiting means of Ge~man ~etters Patent 41 ~4 385, any ~nd all pau~e in administration i~ foregone and a uniform estrogen level, particularly on the basis of ethinyl estradiol, is main-tained oVer the entire cycle of, ~or exa~ple, 2a days. As a res~lt ~hereof, an es~entially constantly elevated concentration of SHBG is effect4d tha~ int~epts the free t~sto~terone, the acne being f~vo~bl~ influenced as a result ther~of.
0~ course, an ovula~l~n-inhi~i~lng ef~ect corres-ponding to the ovulation-inhibiting means of German Pub-lis~ed Application 41 04 38S al~o oc:curs given the mean6 of the invention, which ~an be po~entially desirablç. The other advantages of maintaining a uniform estrogen level as des~ribed in German Let~ers Patent 41 04 385, this being achieve~ ~y avoidlng any and all pause in ad~ini~tration~
E~CIEHI~IERT l E0EH~IERT RN:0001513~337g41 1~15. 12-21 13:38 #680 F.0C;/ll . .... .. .... . ... ... . .. ... ... ............ . .. . .. . ..... ... .. .. .
are also ~eneficially achie~ed in the administration of the means of the invention.
Further features of the invention derive ~rom the ~ollowing de~cription wherein exemplary embodiments are S explained.
ECIEHMEPT + E:OEHI~IE~T F~ ;l32337~4l 1~5,1~-21 13:~ #6~ P.07/11 ............... . .. .. ~ .. . . .. .. .. ... ..... ....... ........ .... ... .... .... ... ..
2 ~ 66 1 2 1 DE~ATT.P.n DESCRIPTION OF THE INVENTION
Exam~le 1:
A oo~ination prepar~tion that c~ntained 7 d~ily unit6 of respectively 20 ~g ethinyl e~tra~iol each as well 5 as ~1 dai}y units o~ re~pe~tiv~ly ZO ~g eth$nyl estradiol and 2 mg ~yproteroneac~ta~e w~ employed for aone therapy.
The ~ormonal regimen was administerçd to a human patien~
s~f~ering from acne for a year and exhibited a very good a~ne-co~batting effect.
ExamPle. ~:
A combination preparatlon that comprised 7 daily units of respe~tl~ely 20 ~g ethinyl ectradiol each and 21 daily units o~ respe~tively 2~ ~g e~hinyl est~adiol and mg chloromadinoneacetate was employed for acne the~py.
Th~ eff$c~y ~orrespon~ed to that of Example 1.
ExamDle 3 A ~om~ination preparation that comprised 7 daily uni~s of respectively 20 ~ ethinyl ectradiol each and 21 daLly unitæ of respectively 20 ~g ethinyl estradiol and 2 mg dieneogest each was employed ~s preparation $or a¢ne therapy. ~he ~iaaay corresponded to that o~ Example 1 and Example 2.
Both individually a~ well as in arbitrary ~ombina-tion, the featureæ of the invention disclosed in the above 25 spe~ifi~ation and in the claims can be critical for reallzing the various e~odi~ents of the invention~
forth above, ~re a matter of combination prepAra~io~s that are also e~ective as ovulation inhibitors in ~ddition to their e~ficacy in combatting acne. In~of~r as the desire~
cycle duration amounts th 28 days, these hormones are admlnistered for 21 days, whereby ~he hormone ~o~blnations are given in 21 daily ~nits, followed by a seven-d~y pause in which no admin~stration of hormone is given. Thi~ pause VC~ EH~lERT + BOEHMERT P~ 01S1~37~41 1g~57 12-21 13: 37 #~;gl21 F .12~
.. . . .. ., . . . ., .. ., .. , . _ . . _ . . .. . . ..... .. ... . .
2l66l2l . .
is followed by a wlthd~awal ~leeding that simulates ~he natural menstru~l ble~dlng.
The prior hormonal ther~pies have definitely pro~en them~elves; however, a further improvement in the ability to ~e able ~o ~ombat acne is 3till desired.
German ~ett~rs Paten~ ~1 04 3B5 dis~lose~ an ovulation-inhibitlng means for hormonal contracep~ion having two hormone con~tituents packaged ~patially separa~ed in a packagin~ unit ~or chronologically sequen-tial, oral admini~tration, each hormone constituent beingre~pectively composed of a plurality o~ ~ily hormone units accom~odated ~patially sep~ratel~ ~nd individually ~e~v-able in thq packaging unit, whereby a first ~f the hormone constituents çontain~ essentially only ~n estrogen prepara-tion as act~ve horm~nal subætan~e that effe~ts a disturb-ance of the follicle stimulation and the second hormon~
constituent contains a combination of an es~rogen prepara-tion and a ~estagen preparation in a dose at least adequate to inhibit ovulati~n, whe~by the ~o~al nu~ber of daily hor~ne units is equal to the total number of days in the desired cy~le, ~he El~st hormone constituent compriseæ 5 through 14 d~lly unt,t~ and the second hormone con6tituent ~omp~ises 23 throug!- 14 dally uni~s, where~y the plurality ~f ~aily units of the first hormone constituent is lower ~5 than the pl~rality of daily units o~ the second hormone ~onstituent.
In this kn~wn ovul~ti~n-inhiblting method, the estrogen preparation can, for ex~ple, comprise ethinyl estradiol and the g6stagen or anti-androgen prep2r~tion can ~ompxi~e cyproteroneacetate or chloromadinoneacet~te.
It is ~:h2~ra~eristi~ o~ the a.bov~-de~cri}~ed ovula~ion-inhi~iting me~ns th~t the adminis~ra~ion ensues without pAuse wi~h a constant estrogen dose, as a result whereof a uniform e8trogen level is maintained.
IJC~ EH~ERT + E~ EH~EF~T R~ 01~161;~337~41 l~lg5. 1~ 37 #~ )4~
SUMMARY OF THE INVENTIO~
The object of the lnvention is to develop an imp~oved hormonal method for tre~tlng ~cne such that an improved a~ne ~her~py i~ enabled.
This o~ject i~ invPnti~ely achieved in th~t the total plurality of daily unit~ is equal ~o ~he t~tal plurality of d~y~ in the desired cycle, in that the first hormon~ constituent comprises 5 ~hrough 14 daily units and ~he ~econd hormone ~onstituent ~omprises ~3 through 14 daily units; and in th~t the plurality of daily uni~5 of the first hormone constituent i5 lower than the plurali~y of daily units of th~ ~econd hormone ~ons~ituent.
It can thereby ~e provided that at least one of the e~trogen preparatlon~ aomprises at least one component from the group encompassing ethinyl e~tradiol, mestranol, o~her syntheti~ es~rogens as well as hormon~l eompounds that ~uickly ~plit off ~t l~ast one of the aforementione~
ho~mone aomponents after ingestion.
The inven~ion also provides that the e~rogen preparations of the first and of the se~ond hormone con~tituen~ ~re identical in terms of their type and/or their effe~tive ~ose.
It c~n ~lso be inven~vely provided that the first and the second hormone con~tituents comprise ethinyl ~S estradiol wi~h ~ concentration of 15 - 35 ~g per dally unit as estrogen preparation.
The in~ention also proposes that the an~i-androgen preparation comprise~ cyproteroneacetate.
It Gan al~o be provided ac~ording to ~he inven~ion th~t the anti-androgen prepar~tlon cont~in~ abou~ mg cyproteroneacet~te per d~ily unit.
A further embodiment of the invention is ~h~ac-teri~ed in that the anti-androgen prep~ration comprises chlorodinoneacetate.
'JCI~I:BClEHMEF:T + E:OEH~`1EF~T I~lN:OE~ 337g41 1~ 1 13:37 #6~1~! p.lZ15~11 _, _ _ _ _ .... . . . . . . . . . .. . . .. . . . . . .. . . . .. . . ... . .
T~e invention also prop~6e~ that the anti-androgen preparation ao~prises approximately 1-3 mg chloro~inone-acetate per d~ily uni~.
The invent~on thereby also propose~ that the anti-andrcgen preparation oo~p~ises dieneogest.
It ~an also be pr~vi~ed that the anti-androgen preparation compri~es approxi~ately 1-3 mg dieneogest per daily unit.
I~ ¢an also be ~nventively provided that thç total numbe~ o~ daily uni~s amounts to Z8.
The ~n~ention also preferably p~ovide~ that the first hormone consti~Uent comprises at mos~ 10 d~ily ~nlts.
In a pre~erred embodimen~ of the method, the firs~
hormone constituent comprises 7 daily units and the sec~n~
hormone constituent comprise~ 21 daily units.
Finally, th~ in~ention also teach~s the employment of the hormonal means of the invention fo~ Acne ~herapy.
The invention is ~ased on ~he surp~i6ing perception that one succeeds in ena~ing an improved acne ~her~py when, in conformi~y with the ovulation-inhibiting means of Ge~man ~etters Patent 41 ~4 385, any ~nd all pau~e in administration i~ foregone and a uniform estrogen level, particularly on the basis of ethinyl estradiol, is main-tained oVer the entire cycle of, ~or exa~ple, 2a days. As a res~lt ~hereof, an es~entially constantly elevated concentration of SHBG is effect4d tha~ int~epts the free t~sto~terone, the acne being f~vo~bl~ influenced as a result ther~of.
0~ course, an ovula~l~n-inhi~i~lng ef~ect corres-ponding to the ovulation-inhibiting means of German Pub-lis~ed Application 41 04 38S al~o oc:curs given the mean6 of the invention, which ~an be po~entially desirablç. The other advantages of maintaining a uniform estrogen level as des~ribed in German Let~ers Patent 41 04 385, this being achieve~ ~y avoidlng any and all pause in ad~ini~tration~
E~CIEHI~IERT l E0EH~IERT RN:0001513~337g41 1~15. 12-21 13:38 #680 F.0C;/ll . .... .. .... . ... ... . .. ... ... ............ . .. . .. . ..... ... .. .. .
are also ~eneficially achie~ed in the administration of the means of the invention.
Further features of the invention derive ~rom the ~ollowing de~cription wherein exemplary embodiments are S explained.
ECIEHMEPT + E:OEHI~IE~T F~ ;l32337~4l 1~5,1~-21 13:~ #6~ P.07/11 ............... . .. .. ~ .. . . .. .. .. ... ..... ....... ........ .... ... .... .... ... ..
2 ~ 66 1 2 1 DE~ATT.P.n DESCRIPTION OF THE INVENTION
Exam~le 1:
A oo~ination prepar~tion that c~ntained 7 d~ily unit6 of respectively 20 ~g ethinyl e~tra~iol each as well 5 as ~1 dai}y units o~ re~pe~tiv~ly ZO ~g eth$nyl estradiol and 2 mg ~yproteroneac~ta~e w~ employed for aone therapy.
The ~ormonal regimen was administerçd to a human patien~
s~f~ering from acne for a year and exhibited a very good a~ne-co~batting effect.
ExamPle. ~:
A combination preparatlon that comprised 7 daily units of respe~tl~ely 20 ~g ethinyl ectradiol each and 21 daily units o~ respe~tively 2~ ~g e~hinyl est~adiol and mg chloromadinoneacetate was employed for acne the~py.
Th~ eff$c~y ~orrespon~ed to that of Example 1.
ExamDle 3 A ~om~ination preparation that comprised 7 daily uni~s of respectively 20 ~ ethinyl ectradiol each and 21 daLly unitæ of respectively 20 ~g ethinyl estradiol and 2 mg dieneogest each was employed ~s preparation $or a¢ne therapy. ~he ~iaaay corresponded to that o~ Example 1 and Example 2.
Both individually a~ well as in arbitrary ~ombina-tion, the featureæ of the invention disclosed in the above 25 spe~ifi~ation and in the claims can be critical for reallzing the various e~odi~ents of the invention~
Claims (14)
.
1. A method for controlling acne comprising:
administering to a human patient suffering from acne two hormone constituents packaged in a packaging unit intended for chronological sequential oral administration, said constituents each comprising a plurality of daily hormone units accommodated specially separate in and individually removable from the packaging unit, wherein a first hormone constituent comprises an estrogen preparation as the sole active hormonal substance which effects an increase in sexual hormone-binding globulins of the patient and a second hormone constituent comprising a combination of an estrogen preparation and an anti-androgen prepara-tion, wherein the total of the daily units is equal to a total number of days in a cycle and the total daily units of the first hormonal constituent is less than the total daily units of the second hormonal constituent.
administering to a human patient suffering from acne two hormone constituents packaged in a packaging unit intended for chronological sequential oral administration, said constituents each comprising a plurality of daily hormone units accommodated specially separate in and individually removable from the packaging unit, wherein a first hormone constituent comprises an estrogen preparation as the sole active hormonal substance which effects an increase in sexual hormone-binding globulins of the patient and a second hormone constituent comprising a combination of an estrogen preparation and an anti-androgen prepara-tion, wherein the total of the daily units is equal to a total number of days in a cycle and the total daily units of the first hormonal constituent is less than the total daily units of the second hormonal constituent.
2. A method as defined in Claim 1, wherein the total number of days in the cycle is 28 and the packaging unit contains 5 to 14 daily units of the first hormone constituent and 23 to 14 daily units of the second hormonal constituent.
3. A method as defined in Claim 1, wherein at least one of the estrogen preparations comprises a com-ponent selected from the group consisting of ethinyl estradiol, mestranol, synthetic, androgens, and hormonal compounds which release ethinyl estradiol, mestranol or synthetic estrogen after ingestion.
4. A method as defined in Claim 1, wherein the estrogen preparation of the first hormone constituent and the second hormone constituent are the same.
5. A method as defined in Claim 1, wherein the estrogen preparation of the first and the second hormone constituents is ethinyl estradiol provided in a concen-tration of from about 15 to about 35 µg per daily unit.
6. A method as defined in Claim 1, wherein in the second hormone constituent the anti-androgen preparation comprises cyproteroneacetate.
7. A method as defined in Claim 1, wherein the anti-androgen preparation comprises from about 1 to about 2 mg cyproteroneacetate per daily unit.
8. A method as defined in Claim 1, wherein the anti-androgen preparation comprises chlorodinoacetate.
9. A method according to Claim 1, wherein the anti-androgen preparation comprises from about 1 to about 3 mg chlorodinoneacetate per daily unit.
10. A method according to Claim 1, wherein the anti-androgen preparation comprises dieneogest.
11. A method according to Claim 1, wherein the anti-androgen preparation comprises from about 1 to about 3 mg dioneogest per daily unit.
12. A method according to Claim 1, wherein the total number of days in the cycle is 28 and the number of daily units of the first hormone constituent is at most 10 daily units.
13. A method as defined in Claim 1, wherein the total number of days in the cycle is 28 and the packaging units contains about 7 daily units of the first hormone constituent and about 21 daily units of the second hormone constituent.
14. A packaged hormonal composition for use in controlling acne comprising:
packaging unit subdivided into separate compartments, each compartment adapted to individually, removably receive a daily dosage unit of a hormone constituent, a plurality of daily dosage units of a first hormone constituent disposed in some of the compartments and a plurality of daily dosage units of a second hormone constituent disposed in others of said compartment, the total number of compartments and daily dosage units being equal to a total number of days in a cycle, the first hormone constituent comprising an estrogen preparation as the sole active hormonal substance which is effective to provide an increase in sexual hormone-binding globulins, the second hormone constituent comprising a combination of an estrogen preparation and an anti-androgen preparation, and wherein the total daily dosage units of the first hormonal constituent is less than the total of the daily dosage units of the second hormonal constituent.
packaging unit subdivided into separate compartments, each compartment adapted to individually, removably receive a daily dosage unit of a hormone constituent, a plurality of daily dosage units of a first hormone constituent disposed in some of the compartments and a plurality of daily dosage units of a second hormone constituent disposed in others of said compartment, the total number of compartments and daily dosage units being equal to a total number of days in a cycle, the first hormone constituent comprising an estrogen preparation as the sole active hormonal substance which is effective to provide an increase in sexual hormone-binding globulins, the second hormone constituent comprising a combination of an estrogen preparation and an anti-androgen preparation, and wherein the total daily dosage units of the first hormonal constituent is less than the total of the daily dosage units of the second hormonal constituent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4321957.8-41 | 1993-07-01 | ||
| DE4321957A DE4321957C2 (en) | 1993-07-01 | 1993-07-01 | Use of a hormonal agent to treat acne |
| PCT/DE1994/000629 WO1995001180A1 (en) | 1993-07-01 | 1994-06-03 | Hormonal agent for the treatment of acne and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2166121A1 true CA2166121A1 (en) | 1995-01-12 |
Family
ID=6491735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002166121A Abandoned CA2166121A1 (en) | 1993-07-01 | 1994-06-03 | Hormonal method of acne therapy |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0710111B1 (en) |
| JP (1) | JPH09500112A (en) |
| AT (1) | ATE205716T1 (en) |
| AU (1) | AU695894B2 (en) |
| BR (1) | BR9407340A (en) |
| CA (1) | CA2166121A1 (en) |
| DE (2) | DE4321957C2 (en) |
| DK (1) | DK0710111T3 (en) |
| ES (1) | ES2164103T3 (en) |
| HU (1) | HUT73234A (en) |
| NO (1) | NO308586B1 (en) |
| PT (1) | PT710111E (en) |
| UA (1) | UA43337C2 (en) |
| WO (1) | WO1995001180A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19534209A1 (en) * | 1995-09-15 | 1997-03-20 | Jenapharm Gmbh | Hormonal agent for the treatment of the skin |
| EP1048673A4 (en) * | 1997-12-26 | 2002-10-25 | Mochida Pharm Co Ltd | Neovascularization inhibitor containing dienogest as the active ingredient |
| DE102004026670A1 (en) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate |
| DE102004026671A1 (en) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Dosage form for hormonal contraception |
| DE102004026679A1 (en) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate |
| DE102006003508A1 (en) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Use of hormone combination of estrogen from ethinyl estradiol and metabolites of chlormadinone acetate, with chlormadione acetate as gestagen components, for producing medicament e.g. for preventing menstruation cycle-dependent mood |
| DE102006003509A1 (en) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Drug delivery system, for hormonal contraception, comprises hormone-containing daily unit, which exhibits estrogen from ethinyl estradiol and estradiol and from metabolite of the chlormadinone acetate optionally with gestagen component |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR79447B (en) * | 1982-12-31 | 1984-10-30 | Mortimer Christopher H Dr | |
| DE3442857A1 (en) * | 1984-11-22 | 1986-05-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Composition for the treatment of androgenisation symptoms in women |
| DE3916112A1 (en) * | 1989-05-16 | 1990-11-22 | Schering Ag | DIHYDROSPIRORENONE AS AN ANTIANDROGEN |
| DE4104385C1 (en) * | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich |
-
1993
- 1993-07-01 DE DE4321957A patent/DE4321957C2/en not_active Expired - Lifetime
-
1994
- 1994-06-03 EP EP94916880A patent/EP0710111B1/en not_active Expired - Lifetime
- 1994-06-03 AT AT94916880T patent/ATE205716T1/en not_active IP Right Cessation
- 1994-06-03 DK DK94916880T patent/DK0710111T3/en active
- 1994-06-03 ES ES94916880T patent/ES2164103T3/en not_active Expired - Lifetime
- 1994-06-03 PT PT94916880T patent/PT710111E/en unknown
- 1994-06-03 JP JP7503202A patent/JPH09500112A/en active Pending
- 1994-06-03 HU HU9503770A patent/HUT73234A/en unknown
- 1994-06-03 DE DE59409869T patent/DE59409869D1/en not_active Expired - Fee Related
- 1994-06-03 WO PCT/DE1994/000629 patent/WO1995001180A1/en active IP Right Grant
- 1994-06-03 UA UA95125308A patent/UA43337C2/en unknown
- 1994-06-03 CA CA002166121A patent/CA2166121A1/en not_active Abandoned
- 1994-06-03 AU AU68408/94A patent/AU695894B2/en not_active Ceased
- 1994-06-03 BR BR9407340A patent/BR9407340A/en not_active Application Discontinuation
-
1995
- 1995-12-29 NO NO955347A patent/NO308586B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE205716T1 (en) | 2001-10-15 |
| EP0710111B1 (en) | 2001-09-19 |
| AU695894B2 (en) | 1998-08-27 |
| EP0710111A1 (en) | 1996-05-08 |
| JPH09500112A (en) | 1997-01-07 |
| DE59409869D1 (en) | 2001-10-25 |
| BR9407340A (en) | 1996-10-08 |
| NO308586B1 (en) | 2000-10-02 |
| WO1995001180A1 (en) | 1995-01-12 |
| ES2164103T3 (en) | 2002-02-16 |
| UA43337C2 (en) | 2001-12-17 |
| DE4321957A1 (en) | 1995-01-12 |
| PT710111E (en) | 2002-02-28 |
| HUT73234A (en) | 1996-07-29 |
| HU9503770D0 (en) | 1996-02-28 |
| AU6840894A (en) | 1995-01-24 |
| DE4321957C2 (en) | 1995-09-28 |
| DK0710111T3 (en) | 2001-12-10 |
| NO955347L (en) | 1995-12-29 |
| NO955347D0 (en) | 1995-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19739916C2 (en) | Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands | |
| US5733902A (en) | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors | |
| DE4308406C1 (en) | Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen | |
| DE19705229C2 (en) | Use of three hormonal components for hormonal contraception for the treatment and / or prophylaxis of tumors of the mammary glands | |
| PL182544B1 (en) | Agent for and method of performing hormonal contraception and/or treating acne | |
| EP0954319A1 (en) | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors | |
| NO179311B (en) | Multiphase combination and contraceptive package | |
| PL186339B1 (en) | Combined contraceptive preparation on natural oestrogen basis | |
| SK10497A3 (en) | Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri | |
| EP0799042A1 (en) | Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception | |
| US4670426A (en) | Interruption of fertility in mammals by post-coital pills | |
| EP1524983B1 (en) | Composition containing an androgenous 11-b-halogen steroid and a progestational hormone, and male contraceptive based on said composition | |
| US7935691B2 (en) | Extended cycle multiphasic oral contraceptive kit | |
| CA2166121A1 (en) | Hormonal method of acne therapy | |
| EP0844880A2 (en) | Contraceptive combined preparation, kits containing the same and contraceptive method using this combined preparation | |
| DE69724796T2 (en) | BIPHASIC ORAL PREVENTION METHOD AND KIT CONTAINING A COMBINATION OF PROGESTINE AND AN ESTROGEN | |
| DD297327A5 (en) | CONTRAZEPTIVE COMPOSITION FOR THE MAN | |
| CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| Mahapatra et al. | Ethinyl Estradiol+ Dienogest. | |
| Aydinlik | Results of an extended open phase III study with | |
| AU2003206424B2 (en) | Sequential estrogen/progesterone antagonist combination for hormone replacement therapy | |
| Gaspard et al. | Clinical, metabolic and endocrine effects of long term use of a cyproterone acetate and ethinyl estradiol combination in hyperandrogenized women | |
| US20080280861A1 (en) | Method of Female Contraception and a Kit For Use Therein | |
| JPH10279483A (en) | Agent for increasing bone density | |
| MXPA06009740A (en) | Extended cycle multiphasic oral contraceptive method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |